Referencias►
1.
Weis M, Mortensen SA, Rassing MR, et al. Bioavailability of four oral coenzyme Q
10
formulations in healthy volunteers.
Mol Aspects Med. 1994;15(suppl):S273 - S280.
2.
Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q
10
therapy in patients with congestive heart failure: a long-term multicenter randomized study.
Clin Investig. 1993;71(8 suppl):S134 - S136.
3.
Hashiba K, Kuramoto K, Ishimi Z, et al.
Heart. 1972;4:1579 - 1589. Cited by: Werbach MR.
Nutritional Influences on Illness
[book on CD-ROM]. Tarzana, Calif: Third Line Press; 1998.
4.
Hofman-Bang C, Rehnquist N, Swedberg K, et al. Coenzyme Q
10
as an adjunctive treatment of congestive heart failure.
J Am Coll Cardiol. 1992;19:216A.
5.
Langsjoen H, Langsjoen P, Langsjoen P, et al. Usefulness of coenzyme Q
10
in clinical cardiology: a long-term study.
Mol Aspects Med. 1994;15(suppl):S165 - S175.
6.
Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q
10.
Proc Natl Acad Sci U S A. 1985;82:4240 - 4244.
7.
Pogessi L, Galanti G, Comeglio M, et al. Effect of coenzyme Q
10
on left ventricular function in patients with dilative cardiomyopathy.
Curr Ther Res.
1991;49:878 - 886.
8.
Digiesi V, Cantini F, Brodbeck B. Effect of coenzyme Q
10
on essential arterial hypertension.
Curr Ther Res. 1990;47:841 - 845.
9.
Langsjoen P, Langsjoen P, Willis R, et al. Treatment of essential hypertension with coenzyme Q
10.
Mol Aspects Med. 1994;15(suppl):S265 - S272.
10.
Digiesi V, Cantini F, Oradei A, et al. Coenzyme Q
10
in essential hypertension.
Mol Aspects Med.
1994;15(suppl):S257 - S263.
11.
Singh RB, Niaz MA, Rastogi SS, et al. Effect of hydrosoluble coenzyme Q
10
on blood pressures and insulin resistance in hypertensive patients with coronary artery disease.
J Human Hypertens.
1999;13:203 - 208.
12.
Watts TL. Coenzyme Q
10
and periodontal treatment: Is there any beneficial effect?
Br Dent J.
1995;178:209 - 213.
13.
Matthews RT, Yang L, Browne S, et al. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects.
Proc Natl Acad Sci U S A.
1998;95:8892 - 8897.
14.
Beal MF. Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases.
Biofactors. 1999;9:261 - 266.
15.
Ylikoski T, Piirainen J, Hanninen O, et al. The effect of coenzyme Q
10
on the exercise performance of cross-country skiers.
Mol Aspects Med.
1997;18(suppl):S283 - S290.
16.
Zuliani U, Bonetti A, Campana M, et al. The influence of Ubiquinone (Co Q
10) on the metabolic response to work.
J Sports Med Phys Fitness.
1989;29:57 - 62.
17.
Weston SB, Zhou S, Weatherby RP, et al. Does exogenous coenzyme Q
10
affect aerobic capacity in endurance athletes?
Int J Sport Nutr.
1997;7:197 - 206.
18.
Malm C, Svensson M, Ekblom B, et al. Effects of ubiquinone-10 supplementation and high intensity training on physical performance in humans.
Acta Physiol Scand.
1997;161:379 - 384.
19.
Snider IP, Bazzarre TL, Murdoch SD, et al. Effects of coenzyme athletic performance system as an ergogenic aid on endurance performance to exhaustion.
Int J Sport Nutr.
1992;2:272 - 286.
20.
Porter DA, Costill DL, Zachwieja JJ, et al. The effect of oral coenzyme Q
10
on the exercise tolerance of middle-aged, untrained men.
Int J Sports Med.
1995;16:421 - 427.
21.
Braun B, Clarkson PM, Freedson PS, et al. Effects of coenzyme Q10 supplementation on exercise performance, VO2max, and lipid peroxidation in trained cyclists.
Int J Sport Nutr. 1991;1:353 - 365.
22.
Bargossi AM, Grossi G, Fiorella PL, et al. Exogenous CoQ
10
supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors.
Mol Aspects Med. 1994;15(suppl):S187 - S193.
23.
Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ
10
-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study.
J Clin Pharmacol. 1993;33:226 - 229.
24.
Mortensen SA, Leth A, Agner E, et al. Dose-related decrease of serum coenzyme Q
10
during treatment with HMG-CoA reductase inhibitors.
Mol Aspects Med. 1997;18(suppl):S137 - S144.
25.
Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans.
Proc Natl AcadSci U S A.
1990; 87:8931 - 8934.
26.
Kishi T, Kishi H, Watanabe T, et al. Bioenergetics in clinical medicine. XI. Studies on Coenzyme Q and diabetes mellitus.
J Med. 1976;7:307 - 321.
27.
Kishi H, Kishi T, Folkers K. Bioenergetics in clinical medicine. III. Inhibition of coenzyme Q
10
-enzymes by clinically used anti-hypertensive drugs.
Res Commun Chem Pathol Pharmacol. 1975;12:533 - 540.
28.
Kishi T, Watanabe T, Folkers K. Bioenergetics in clinical medicine XV. Inhibition of coenzyme Q
10
-enzymes by clinically used adrenergic blockers of beta-receptors.
Res Commun Chem Pathol Pharmacol. 1977;17:157 - 164.
29.
Folkers K. Basic chemical research on coenzyme Q
10
and integrated clinical research on therapy of diseases.
Biomed Clin Aspects Coenzyme Q.
1985;5:457 - 478.
30.
Kishi T, Makino K, Okamoto T, et al. Inhibition of myocardial respiration by psychotherapeutic drugs and prevention by coenzyme Q.
Biomed Clin Aspects Coenzyme Q.
1980;4:139 - 157.
31.
Hamada M, Kazatain Y, Ochi T, et al. Correlation between serum CoQ
10
level and myocardial contractility in hypertensive patients.
Biomed Clin Aspects Coenzyme Q.
1984;4:263 - 270.
32.
Werbach MR.
Nutritional Influences on Illness
[book on CD-ROM]. Tarzana, Calif: Third Line Press; 1998.
33.
Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q
10
therapy in patients with congestive heart failure: a long-term multicenter randomized study.
Clin Investig. 1993;71(8 suppl):S134 - S136.
34.
Hashiba K, Kuramoto K, Ishimi Z, et al.
Heart. 1972;4:1579 - 1589. Cited by: Werbach MR.
Nutritional Influences on Illness
[book on CD-ROM]. Tarzana, Calif: Third Line Press; 1998.
35.
Hofman-Bang C, Rehnquist N, Swedberg K, et al. Coenzyme Q
10
as an adjunctive treatment of congestive heart failure.
J Am Coll Cardiol. 1992;19:216A.
36.
Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure.
Ann Intern Med. 2000;132:636-640.
37.
Langsjoen H, Langsjoen P, Langsjoen P, et al. Usefulness of coenzyme Q
10
in clinical cardiology: a long-term study.
Mol Aspects Med. 1994;15(suppl):S165 - S175.
38.
Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q
10.
Proc Natl Acad Sci U S A. 1985;82:4240 - 4244.
39.
Pogessi L, Galanti G, Comeglio M, et al. Effect of coenzyme Q
10
on left ventricular function in patients with dilative cardiomyopathy.
Curr Ther Res.
1991;49:878 - 886.
40.
Singh RB, Niaz MA, Rastogi SS, et al. Effect of hydrosoluble coenzyme Q
10
on blood pressures and insulin resistance in hypertensive patients with coronary artery disease.
J Human Hypertens.
1999;13:203 - 208.
41.
Digiesi V, Cantini F, Brodbeck B. Effect of coenzyme Q
10
on essential arterial hypertension.
Curr Ther Res. 1990;47:841 - 845.
42.
Langsjoen P, Langsjoen P, Willis R, et al. Treatment of essential hypertension with coenzyme Q
10.
Mol Aspects Med. 1994;15(suppl):S265 - S272.
43.
Digiesi V, Cantini F, Oradei A, et al. Coenzyme Q
10
in essential hypertension.
Mol Aspects Med.
1994;15(suppl):S257 - S263.
44.
Lampertico M, Comis S. Italian multicenter study on the efficacy and safety of coenzyme Q
10
as adjuvant therapy in heart failure.
Clin Investig. 1993;71(8 suppl):S129 - S133.
45.
Singh RB, Niaz MA, Rastogi SS, et al. Effect of hydrosoluble coenzyme Q
10
on blood pressures and insulin resistance in hypertensive patients with coronary artery disease.
J Human Hypertens.
1999;13:203 - 208.
46.
Eriksson JG, Forsen TJ, Mortensen SA, et al. The effect of coenzyme Q
10
administration on metabolic control in patients with type 2 diabetes mellitus.
Biofactors.
1999;9:315 - 318.
47.
Spigset O. Reduced effect of warfarin caused by ubidecarenone [letter].
Lancet.
1994;344:1372 - 1373.
48.
Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q
10
and remacemide in Huntington's disease.
Neurology.
2001;57:397 - 404.
49.
Singh RB, Khanna HK, Niaz MA. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in chronic renal failure: discovery of a new role.
J Nutr Environ Med. 2000;10:281-288.
50.
Burke BE, Neuenschwander R, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension.
South Med J. 2001;94:1112 - 1117.
51.
Munkholm H, Hansen HH, Rasmussen K. Coenzyme Q10 treatment in serious heart failure.
Biofactors. 1999;9:285-289.
52.
Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure.
J Am Coll Cardiol. 1999;33:1549-1552.
53.
Munkholm H, Hansen HH, Rasmussen K. Coenzyme Q10 treatment in serious heart failure.
Biofactors. 1999;9:285-289.
54.
Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure.
J Am Coll Cardiol. 1999;33:1549-1552.
55.
Combs AB, Porter TH, Folkers K. Anticoagulant activity of a naphtoquinone analog of vitamin K and an inhibitor of coenzyme Q
10
-enzyme systems.
Res Commun Chem Pathol Pharmacol.
1976;13:109 - 114.
56.
Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q
10
and
Ginkgo biloba
on warfarin dosage in stable, long-term warfarin-treated outpatients. A randomised, double-blind, placebo-crossover trial.
Thromb Haemost.
2002;87:1075-1076.
57.
Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme q10 in early Parkinson disease: evidence of slowing of the functional decline.
Arch Neurol.
2002;59:1541-1550.
58.
Hodgson JM, Watts GF, Playford DA, et al. Coenzyme Q(10) improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes.
Eur J Clin Nutr. 2002;56:1137-1142.
59.
Combs AB, Choe JY, Truong DH, et al. Reduction by coenzyme Q10 of the acute toxicity of adriamycin in mice.
Res Commun Chem Pathol Pharmacol. 1977;18:565-568.
60.
Judy WV, Hall JH, Dugan W, et al. Coenzyme Q10 reduction of Adriamycin cardiotoxicity.
Biomed Clin Aspects Coenzyme Q.
1984;4:231-241.
61.
Sugiyama S, Yamada K, Hayakawa M, et al. Approaches that mitigate doxorubicin-induced delayed adverse effects on mitochondrial functions in rat hearts; Liposome-encapsulated doxorubican or combination therapy with antioxidant.
Biochem Mol Biol Int.
1995;36:1001-1007.
62.
Eriksson JG, Forsen TJ, Mortensen SA, et al. The effect of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus.
Biofactors.
1999;9:315 - 318.
63.
Singh RB, Wander GS, Rastogi A, et al. Randomized double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction.
Cardiovasc Drugs Ther.
1998;12:347 - 353.
64.
Kuklinski B, Weissenbacher E, Fahnrich A. Coenzyme Q10 and antioxidants in acute myocardial infarction.
Mol Aspects Med. 1994;15 Suppl:S143 - S147.
65.
Muller T, Buttner T, Gholipour AF, et al. Coenzyme Q(10) supplementation provides mild symptomatic benefit in patients with Parkinson's disease.
Neurosci Lett.
2003;341:201 - 204.
